Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells $150,137.94 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 258 shares of United Therapeutics stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $581.93, for a total value of $150,137.94. Following the completion of the transaction, the director directly owned 5,028 shares of the company’s stock, valued at approximately $2,925,944.04. This represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Price Performance

NASDAQ UTHR opened at $568.58 on Friday. The company has a market cap of $24.14 billion, a P/E ratio of 20.99, a P/E/G ratio of 1.82 and a beta of 0.60. The stock has a 50-day moving average of $558.07 and a two-hundred day moving average of $507.08. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.63 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.5 million, trimming her stake by 19%; CFO James Edgemond also sold 10,000 shares for about $5.7 million, reducing his ownership by 34.6%. These sizable insider transactions can make investors cautious about near-term sentiment. Article Title
• Neutral Sentiment: Director Nilda Mesa also sold 258 shares, a smaller transaction that adds to the recent insider selling trend. Article Title
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $660 price target, despite trimming its FY2030 earnings estimate slightly. Broader analyst coverage remains constructive, with a consensus rating of Moderate Buy and a target around $619.42, which may help support the stock. Article Title

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AE Wealth Management LLC lifted its stake in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC lifted its stake in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new stake in United Therapeutics in the third quarter valued at approximately $444,000. Tobam lifted its stake in United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock valued at $3,205,000 after buying an additional 4,953 shares during the last quarter. Finally, Perpetual Ltd purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $1,059,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. TD Cowen upped their price target on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a report on Monday, March 30th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Bank of America upped their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Finally, Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.